Toggle light / dark theme

The Man Who Would Stop Time

Circa 2011


Bill Andrews’s feet are so large, he tells me, that back when he was 20 he was able to break the Southern California barefoot-waterskiing distance record the first time he put skin to water. Then he got ambitious and went for the world speed record. When the towrope broke at 80 mph, he says, “they pulled me out of the water on a stretcher.”

The soles of the size-15 New Balances that today shelter those impressive feet strike a steady clap-clap on the macadam as Andrews and I lope down a path along the Truckee River that takes us away from the clutter of cut-rate casino hotels, strip malls and highway exit ramps that is downtown Reno, Nevada. Andrews, 59, is a lean 6-foot-3 and wears a close-cropped salt-and-pepper Vandyke and, for today’s outing, a silver running jacket, nicely completing a package that suggests a Right Stuff–era astronaut. He is in fact one of the better ultramarathoners in America. I am an out-of-shape former occasional runner, so it gives me pause to listen as Andrews describes his racing exploits. “I can run 100 miles, finish, turn around, and meet friends of mine on the course who are still coming in,” he says. “I’ve been in many races where I’m stepping over bodies of people who have collapsed, and I’m feeling great.”

“I want to cure my aging, my friends’ and family’s aging, my investors’ aging, and I want to make a ton of money,” Andrews says. His return to running after a middle-aged break was, he says, inspired by a revelation he had at a time when he and a small team of scientists at his biotech start-up, Sierra Sciences, had been working 14 to 18 hours a day in the lab for five years, rather obsessively pursuing a particular breakthrough. Finally, his doctor told him he was headed for an early grave. “I thought, god, I don’t want to cure aging and then drop dead,” Andrews says.

A new CRISPR/Cas9 therapy can suppress aging

LA JOLLA—(February 18, 2019) Aging is a leading risk factor for a number of debilitating conditions, including heart disease, cancer and Alzheimer’s disease, to name a few. This makes the need for anti-aging therapies all the more urgent. Now, Salk Institute researchers have developed a new gene therapy to help decelerate the aging process.

The findings, published on February 18, 2019 in the journal Nature Medicine, highlight a novel CRISPR/Cas9 genome-editing that can suppress the accelerated aging observed in mice with Hutchinson-Gilford progeria syndrome, a rare genetic disorder that also afflicts humans. This treatment provides important insight into the molecular pathways involved in accelerated aging, as well as how to reduce toxic proteins via .

“Aging is a complex process in which cells start to lose their functionality, so it is critical for us to find effective ways to study the molecular drivers of aging,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the paper. “Progeria is an ideal aging model because it allows us to devise an intervention, refine it and test it again quickly.”

Excessive Cell Size Contributes to Senescence

In a new study [1], researchers have identified the reason why cells become defective when they grow too large and why protein creation fails when cells grow larger than their original healthy size, as is typically seen in aged and senescent cells.

They demonstrate that in enlarged yeast and human cells, RNA and protein biosynthesis does not scale in proportion to the additional cell size, which then leads to a dilution of the cytoplasm. This phenomenon is also present in senescent cells, which display similar traits to those of large cells.

The research team concludes that the maintenance of a cell type-specific DNA-to-cytoplasm ratio is essential for the majority of cellular functions, and when cellular growth changes this ratio, it encourages cells to become senescent.

These are the Russian-speaking Jewish Americans you never knew changed your life

Clockwise from top left: ‘Hammer and Silicon’ authors Daniel Satinsky, Sheila Puffer, and Daniel McCarthy (Courtesy Sheila Puffer); scientist Slava Epstein (Adam Glanzman/ Northeastern University); Vladimir Torchilin, director of pharmaceutical biotechnology and nanomedicine at Northeastern University; anti-aging researcher at Harvard, Vadim Gladyshev (YouTube screenshot).


From cancer research to designing systems powering the Eiffel Tower, the unsung scientists, inventors and entrepreneurs found in the new book ‘Hammer and Silicon’ make an impact.

British woman is first in the world to undergo gene therapy for most common form of blindness

A British woman has become the first person in the world to undergo gene therapy for the most common cause of sight loss.

Surgeons at the John Radcliffe Hospital in Oxford inserted a synthetic gene into the left eye of Janet Osborne, 80, who suffers from age-related macular degeneration (AMD).

Around 600,000 people in the UK are affected by AMD, which affects the central part of a patient’s vision with gaps or ‘smudges’, making everyday activities like reading and recognising faces difficult.

Liz Parrish : Gene therapy advancements | BioViva | People Unlimited

Liz talking about Rutgers, Integrated Health Systems, anti-aging vaccine(couple of years of gathering data), $75,000 single organ treatment, and potential for very affordable whole body treatment. Q&A at 32 minutes.


Liz Parrish | BioViva, presents at People Unlimited’s Ageless Education, about Gene Therapy Advancements.

The Ageless Education series brings in many of the leading figures in radical life extension to share their views on the most cutting edge strategies for living long enough to live forever.

For more info: http://www.peopleunlimitedinc.com

People Unlimited is an educational, lifestyle and social organization for people interested in living unlimited lifespans.

CRISPR gene editing makes stem cells ‘invisible’ to immune system

UC San Francisco scientists have used the CRISPR-Cas9 gene-editing system to create the first pluripotent stem cells that are functionally “invisible” to the immune system, a feat of biological engineering that, in laboratory studies, prevented rejection of stem cell transplants. Because these “universal” stem cells can be manufactured more efficiently than stem cells tailor-made for each patient—the individualized approach that dominated earlier efforts—they bring the promise of regenerative medicine a step closer to reality.

“Scientists often tout the therapeutic potential of pluripotent stem cells, which can mature into any adult tissue, but the immune system has been a major impediment to safe and effective stem cell therapies,” said Tobias Deuse, MD, the Julien I.E. Hoffman, MD, Endowed Chair in Cardiac Surgery at UCSF and lead author of the new study, published Feb. 18 in the journal Nature Biotechnology.

The immune system is unforgiving. It’s programmed to eradicate anything it perceives as alien, which protects the body against infectious agents and other invaders that could wreak havoc if given free rein. But this also means that transplanted organs, tissues or cells are seen as a potentially dangerous foreign incursion, which invariably provokes a vigorous immune response leading to transplant rejection. When this occurs, donor and recipient are said to be—in medical parlance—” histocompatibility mismatched.”

/* */